Global Hepatitis B Vaccines Market 2014-2018

世界のB型肝炎ワクチン市場(2014-2018)

◆タイトル:Global Hepatitis B Vaccines Market 2014-2018
◆商品コード:IRTNTR3995
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年8月27日
◆ページ数:91
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界のB型肝炎ワクチン市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、需要先別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Hepatitis B Vaccines
Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of the liver cells. Following the viral infection, the immune system is activated against virus and hepatocytes infected with viruses. This, in turn, leads to the inflammation of the liver. Extra-hepatic manifestations of hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person at the time of infection and infecting dose of virus are important factors that determine the severity of acute or chronic hepatitis B. Most of the patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines.

TechNavio’s analysts forecast the Global Hepatitis B Vaccines market to grow at a CAGR of 4.00 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Hepatitis B Vaccines market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various vaccines intended for active immunization against different serogroups of hepatitis B virus. In terms of composition, the Global Hepatitis B Vaccines market can be segmented into the following: Mono Vaccines and Combination Vaccines.

TechNavio’s report, the Global Hepatitis B Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis B Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• GlaxoSmithKline
• Merck
• Sanofi Pasteur

Other Prominent Vendors
• Dynavax Technologies
• Janssen Pharmaceuticals
• LG Life Sciences
• Kaketsuken
• Shenzhen Kangtai Biological Products

Market Driver
• Increased Awareness about Hepatitis B Infection and Prevention
• For a full, detailed list, view our report

Market Challenge
• Inadequate Vaccine Coverage
• For a full, detailed list, view our report

Market Trend
• Combination Vaccines
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Hepatitis B: Acute and Chronic Infection
05.2 Hepatitis B: Geographical Distribution
05.3 Hepatitis B: Estimated National Immunization Coverage
05.3.1 Hepatitis B Birth Dose Vaccine
05.3.2 Third Dose of Hepatitis B Vaccine
05.4 Chronic Disease Prone Individuals for Hepatitis B
05.5 Hepatitis B: Diagnosis
05.5.1 Serological Markers
05.5.2 Hepatitis B Serologic Test Interpretation
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Composition
08.1 Mono Vaccines
08.2 Combination Vaccines
09. Market Segmentation by End-user Age Group
09.1 Global Adult Hepatitis B Vaccines Market
09.1.1 Market Size and Forecast
09.1.2 Geographical Segmentation
09.2 Global Pediatric Hepatitis B Vaccines Market
09.2.1 Market Size and Forecast
10. Geographical Segmentation
10.1 Global Hepatitis B Vaccines Market in the Americas
10.1.1 Market Size and Forecast
10.2 Global Hepatitis B Vaccines Market in the EMEA Region
10.2.1 Market Size and Forecast
10.3 Global Hepatitis B Vaccines Market in the APAC Region
10.3.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.2.1 GlaxoSmithKline
18.2.2 Sanofi Pasteur
18.2.3 Merck
18.3 Other Prominent Vendors and Future Players
19. Late-stage Pipeline Candidates
19.1 Key Information for Late-stage Pipeline Candidates
19.1.1 PR5I
19.1.2 Heplisav-B
20. Key Vendor Analysis
20.1 GlaxoSmithKline
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Sales by Geography
20.1.6 Pipeline Products
20.1.7 Business Strategy
20.1.8 Key Information
20.1.9 SWOT Analysis
20.2 Merck
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue 2013
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Business Strategy
20.2.7 Key Developments
20.2.8 SWOT Analysis
20.3 Sanofi Pasteur
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Strategy
20.3.4 Recent Developments
20.3.5 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Pathway of Hepatitis B Progression
Exhibit 3: Number of Hepatitis B Birth Doses Administered in WHO Regions
Exhibit 4: Trend of Hepatitis B Birth Doses Administered in WHO Regions 2000-2013
Exhibit 5: Percentage Share of Different Regions in 2013
Exhibit 6: Number of Third Doses of Hepatitis B Administered in WHO Regions
Exhibit 7: Trend of Third Doses of Hepatitis B Administered in WHO Regions 2000-2013
Exhibit 8: Percentage Share of Different Regions in 2013
Exhibit 9: Comparison of Third Dose and Birth Dose in 2013 in WHO Regions
Exhibit 10: Disease Progression of Hepatitis B
Exhibit 11: Significance of Serological Markers
Exhibit 12: Interpretation of Serological Markers
Exhibit 13: Global Hepatitis B Vaccines Market 2013-2018 (US$ million)
Exhibit 14: Global Hepatitis B Vaccines Market Segmentation by Composition
Exhibit 15: Dosage Regimen of Engerix-B
Exhibit 16: Dosage Regimen of Fendrix
Exhibit 17: Dosage Regimen of Recombivax HB
Exhibit 18: Dosage Regimen of Infanrix hexa
Exhibit 19: Dosage Regimen of Hexacima/Hexyon
Exhibit 20: Dosage Regimen of Twinrix
Exhibit 21: Dosage Regimen of Ambirix
Exhibit 22: Dosage Regimen of Comvax
Exhibit 23: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group
Exhibit 24: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013
Exhibit 25: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013-2018 (US$ million)
Exhibit 26: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013-2018
Exhibit 27: Global Adult Hepatitis B Vaccines Market 2013-2018 (US$ million)
Exhibit 28: Global Adult Hepatitis B Vaccines Market by Geography Segmentation
Exhibit 29: Global Pediatric Hepatitis B Vaccines Market 2013-2018 (US$ million)
Exhibit 30: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013
Exhibit 31: Global Hepatitis B Vaccines Market by Geographical Segmentation 2018
Exhibit 32: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013-2018 (US$ million)
Exhibit 33: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013-2018
Exhibit 34: Hepatitis B Vaccines Market in the Americas 2013-2018 (US$ million)
Exhibit 35: Hepatitis B Vaccines Market in the EMEA Region 2013-2018 (US$ million)
Exhibit 36: Hepatitis B Vaccines Market in the APAC Region 2013-2018 (US$ million)
Exhibit 37: Territories with Moderate to High Risk of Developing Hepatitis B Infection
Exhibit 38: Benefits of Combination Vaccines
Exhibit 39: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 40: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 41: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 42: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 43: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 44: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 45: Merck & Co. Inc.: Sales by Geography 2013



【掲載企業】

GlaxoSmithKline, Merck, Sanofi Pasteur , Dynavax Technologies, Janssen Pharmaceuticals, LG Life Sciences, Kaketsuken, Shenzhen Kangtai Biological Product

【資料のキーワード】

B型肝炎ワクチン、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[世界のB型肝炎ワクチン市場(2014-2018)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆